Valuation: Dermata Therapeutics, Inc.

Market Cap 3.07M 2.76M 2.52M 2.3M 4.33M 289M 4.47M 30.36M 12.11M 154M 11.53M 11.29M 487M P/E 2026 *
-0.35x
P/E 2027 * -0.53x
Enterprise Value 3.07M 2.76M 2.52M 2.3M 4.33M 289M 4.47M 30.36M 12.11M 154M 11.53M 11.29M 487M EV / Sales 2026 *
30.7x
EV / Sales 2027 * 4.1x
Free-Float
77.8%
Yield 2026 *
-
Yield 2027 * -
1 day+0.28%
1 week-1.42%
Current month-1.42%
1 month-32.39%
3 months-31.17%
6 months-39.84%
Current year-67.07%
1 week 0.72
Extreme 0.7201
0.91
1 month 0.6
Extreme 0.6032
1.18
Current year 0.6
Extreme 0.6032
4.66
1 year 0.6
Extreme 0.6032
4.66
3 years 0.6
Extreme 0.6032
146.25
5 years 0.6
Extreme 0.6032
14,222.87
10 years 0.6
Extreme 0.6032
16,679.99
Manager TitleAgeSince
Chief Executive Officer 67 08/12/2014
Director of Finance/CFO 48 01/09/2021
Investor Relations Contact - -
Director TitleAgeSince
Chairman 67 01/04/2021
Director/Board Member 77 08/12/2014
Director/Board Member 78 20/09/2016
Date Insider Type Main position Quantity % Market Cap. Importance
16/08/26 Free

Chief Financial Officer

306,120 10.7966%
17/02/26 Buy

General Counsel

1,000 0.0353%
02/01/26 Free

Director

2,500 0.0940%
Change 5-day change 1-year change 3-year change Capi.($)
+0.28%-1.42%-74.10%-99.39% 3.07M
-4.83%+3.51%+53.62%+61.75% 65.94B
-1.34%+2.98%+24.79%+100.18% 56.53B
+0.02%+1.07%+10.63%+76.66% 56.88B
+5.09%+9.89%+22.45%+107.48% 46.49B
+2.62%+1.68%+28.91%+37.01% 44.8B
+8.24%+0.51%+213.26%+792.66% 41.59B
-1.86%+10.13%+26.82%+53.22% 35.35B
-2.97%-9.84%+88.86%+76.17% 33.29B
-2.18%+7.06%+36.06%-4.95% 24.92B
Average +0.31%+2.78%+43.13%+120.08% 40.58B
Weighted average by Cap. +0.21%+3.40%+53.12%+142.95%

Financials

2026 *2027 *
Net sales 100K 89.69K 81.97K 74.82K 141K 9.4M 145K 988K 394K 5.02M 375K 367K 15.83M 750K 673K 615K 561K 1.06M 70.5M 1.09M 7.41M 2.95M 37.62M 2.82M 2.75M 119M
Net income -11.08M -9.94M -9.08M -8.29M -15.62M -1.04B -16.12M -110M -43.66M -556M -41.6M -40.71M -1.75B -13.78M -12.36M -11.3M -10.31M -19.43M -1.3B -20.04M -136M -54.3M -691M -51.73M -50.62M -2.18B
Net Debt - -
Projected Income Statement - Annual - Dermata Therapeutics, Inc.
Logo Dermata Therapeutics, Inc.
Dermata Therapeutics, Inc. is a late-stage medical dermatology company. The Company is focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. Its two product candidates, XYNGARI and DMT410, both incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its lead product candidate, XYNGARI, is intended to utilize its Spongilla technology for once weekly treatment of a variety of skin diseases, with its initial focus being the treatment of acne vulgaris, which has a United States market size of approximately 30 million patients seeking treatment. The Company’s second product candidate, DMT410, uses its XYNGARI product candidate as a new method for needle-free intradermal delivery of botulinum toxin for the treatment of multiple aesthetic applications and medical skin diseases.
Employees
9
Date Price Change Volume
06/11/26 $0.7640 +0.28% 60,213
05/11/26 $0.7619 -10.87% 50,624
04/11/26 $0.8548 +0.72% 51,986
03/11/26 $0.8487 +12.59% 226,043
02/11/26 $0.7538 -2.74% 141,372
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
0.7640USD
Average target price
4.000USD
Spread / Average Target
+423.56%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Dermata Therapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. DRMA Stock